LOUISVILLE, Ky., April 5, 2019 /PRNewswire/ — NX Prenatal Inc. (“NX Prenatal”) today announced that it has entered into a strategic collaboration with Thermo Fisher Scientific. The collaboration is designed to expand upon integrated workflows that the companies have established to enable high volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome® platform.
NX Prenatal’s NeXosome technology harvests biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal tissues. This technology is key in NX Prenatal’s development of a series of early warning blood tests for pregnancies that may result in a variety of adverse outcomes, such as spontaneous preterm birth and preeclampsia.
“Thermo Fisher is a world leader in proteomics, and its liquid chromatography-mass spectrometry (LC-MS) instrumentation is an enabling technology for the new era of personalized medicine,” commented Kevin P. Rosenblatt, MD, PhD, Chief Medical and Scientific Officer of NX Prenatal.
Terms of the multi-year collaboration were not disclosed.
About NX Prenatal
NX Prenatal Inc. is a private, US-based molecular diagnostics company. The company’s proprietary NeXosome® platform is being utilized to develop enabling, early warning systems for pregnancies that may result in spontaneous preterm birth, preeclampsia and other adverse outcomes. For more information, please visit the company’s website at www.nxprenatal.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/nx-prenatal-enters-collaboration-to-develop-high-throughput-clinical-mass-spec-proteomic-assays-for-nexosome-platform-300825570.html
SOURCE NX Prenatal Inc.
DUBLIN--(BUSINESS WIRE)--The "United States Pharmacovigilance Market, By Region, Competition Forecast and Opportunities, 2018-2028F" report has…
The psychiatry and behavioral health group to utilize practice management and patient engagement solutions to…
NEW YORK--(BUSINESS WIRE)--Nym, the leader in autonomous medical coding, today announced that it has been…
LONDON--(BUSINESS WIRE)--#advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call…
Seasoned financial leader brings experience at leading companies in healthcare and software as a service…
The DynamX BTK System for the treatment of BTK vessels impacted by CLTI broadens the…